ACTU Actuate Therapeutics: Net Sales Margin

Actuate Therapeutics Inc. - graphic logo of issuer ACTU

Actuate Therapeutics, Inc. (ACTU) is rapidly expanding its influence within the oncology community by developing effective inhibitors. The marginal realization profile demonstrates current resilience, with the 0.00 mark recording this metric. The environmental footprint is minimized due to the laboratory-based operational format. Business stability relies on the development of targeted therapy in US centers and successful clinical trials.

ACTU: Actuate Therapeutics Inc Company Net Profitability 08/14/2024 - 11/20/2026

Actuate Therapeutics, Inc. (ACTU) - metric breakdowns and financial figures

- share price and consensus valuation forecast:
Fundamental company valuation:Actuate Therapeutics - ACTU
Finished products of Actuate Therapeutics Inc

For the long-term investor, the reliability of Actuate Therapeutics, Inc. (ACTU) is determined by its ability to preserve capital amidst geopolitical barriers that restrict global clinical trials. By analyzing the current sales margin, which measures the portion of net profit in every dollar of revenue, one can assess the real operational efficiency of the business and its resilience to risks associated with delays in the registration of innovative drugs.

Who Actuate Therapeutics, Inc. competes with

ONC: Net Sales Margin|Net Margin Halozyme Inc. (HALO)|Net Margin RevMed|Net Return on Sales AAPG (Ascentage Pharma Group)|Net Sales Margin CGON|UroGen Pharma - Net Return on Sales|Bicara Therapeutics - Return on Sales by Net Profit|Net Sales Margin Personalis Inc PSNL|Erasca Oncology - Net Sales Margin|Net Profit Rate DCTH (Delcath Corp)|YMAB: Net Sales Margin|AURA - Company Sales Margin|CADL (Candel Therapeutics Inc.) - Net Sales Margin|Net Return on Sales ARAY (Accuray)|Return on Sales by Net Profit SLS (SELLAS Life Sciences Group, Inc.)|CTOR - Net Margin|Net Sales Margin HURA (TuHURA Biosciences, Inc.)|Net Profit Rate TARA|FATE: Return on Sales by Net Profit|WHWK (aadibio.com) - Net Return on Sales|TCRX (TScan Therapeutics, Inc.) - Return on Sales by Net Profit|Net Margin Champions Oncology Corp (CSBR)|XBIT (XBiotech Inc.) - Net Sales Margin|CVM (CEL-SCI Corporation) - Company Net Profitability|Net Sales Margin OSTX|Net Sales Margin Radiopharm Theranostics Ltd (RADX)|Net Sales Margin ARTV (Artiva Biotherapeutics)|Net Sales Margin Adlai Nortye Ltd. ANL|Veru Inc - Net Sales Margin|Company Sales Margin Tempest Therapeutics TPST|XLO: Net Sales Margin|Enochian BioSciences (RENB) - Net Sales Margin|Return on Sales by Net Profit MURA|Kairos Pharma Ltd - Net Profit Margin|Net Sales Margin OKUR|CytoMed Therapeutics Limited (GDTC) - Net Profitability Margin|Net Sales Margin CRIS (Curis, Inc.)|APLM: Net Return on Sales|Tharimmune Corporation - Net Sales Margin|ADVB: Net Margin|GNPX: Net Sales Margin|CLDI (Calidi Biotherapeutics Inc.) - Net Margin|Net Margin Sunshine Biopharma, Inc.|Net Sales Margin xeneticbio.com|Net Margin Salarius (SLRX)|Return on Sales by Net Profit Purple Biotech PPBT|Net Margin American Oncology Network, Inc. AONC|BeiGene, Ltd. (BGNE) - Net Margin|Checkpoint Therapeutics Inc. - Net Sales Margin|Net Profit Rate ELEV (Elevation Oncology)|ICAD (iCAD Corp) - Return on Sales by Net Profit|Ikena Oncology, Inc. - Net Profit Rate|Return on Sales by Net Profit NTBL|VIRX: Net Profit Rate|Net Margin MorphoSys Corporation (MOR)|NAYA - Net Margin|Net Sales Margin AAPGV (Ascentage)